Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.
Mod Rheumatol
; 32(1): 74-86, 2022 Jan 05.
Article
in En
| MEDLINE
| ID: mdl-33706664
ABSTRACT
OBJECTIVES:
To evaluate the efficacy and safety of biosimilars compared with reference biological disease modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) as a part of the process of developing the 2020 update of the Japan College of Rheumatology guidelines for the management of RA.METHODS:
PubMed, Cochrane Library, and Japan Centra Revuo Medicina were searched for articles to conduct a systematic review (SR). The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation system.RESULTS:
Twenty randomized controlled trials were included (biosimilars of infliximab, etanercept, and adalimumab). A meta-analysis revealed that the risk ratios (RRs) and 95% confidence intervals (CIs) of achieving the American College of Rheumatology 50% response (ACR50) at week 24 and serious adverse events (SAEs) for biosimilars compared with the reference bDMARDs were 1.04 (0.98-1.10) and 0.84 (0.61-1.18), respectively. The RRs of achieving ACR50 and SAEs at week 24 were respectively 0.93 (0.69-1.26) and 2.15 (0.55-8.35) in the patients who switched to biosimilars from the reference bDMARDs and 0.92 (0.76-1.12) and 1.41 (0.32-6.15) in those who continued the reference bDMARDs.CONCLUSION:
Biosimilars and reference bDMARDs were equally useful for the management of RA.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Rheumatology
/
Antirheumatic Agents
/
Biosimilar Pharmaceuticals
Type of study:
Clinical_trials
/
Guideline
/
Systematic_reviews
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Year:
2022
Type:
Article